
    
      The selection of CD34+ cells is associated with the simultaneous depletion of T cells that
      are responsible for severe acute and chronic graft versus host disease (GVHD). Successful
      engraftment is reported in adult patients with malignant and non-malignant disease who
      received CD34+ selected stem cells from HLA-matched or mismatched mobilized peripheral blood
      (PBSC) or bone marrow.

      Study Design:

      Selected patients defined in the eligibility criteria will enrolled on this study. Patients
      will receive one of either full intensity or reduced intensity regimen based on the patient's
      disease status, organ function and performance and determined by the PI and will have
      peripheral blood undergo CD34 selection.
    
  